CH491873A - Process for the preparation of phenylalkylaminoguanidines - Google Patents

Process for the preparation of phenylalkylaminoguanidines

Info

Publication number
CH491873A
CH491873A CH801766A CH801766A CH491873A CH 491873 A CH491873 A CH 491873A CH 801766 A CH801766 A CH 801766A CH 801766 A CH801766 A CH 801766A CH 491873 A CH491873 A CH 491873A
Authority
CH
Switzerland
Prior art keywords
hydrogen nitrate
addition salts
acid addition
phenylalkylaminoguanidines
formula
Prior art date
Application number
CH801766A
Other languages
German (de)
Inventor
Bernard Bream John
Wolfgang Dr Picard Claude
George White Trevor
Original Assignee
Wander Ag Dr A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wander Ag Dr A filed Critical Wander Ag Dr A
Priority to CH801766A priority Critical patent/CH491873A/en
Priority to CH898866A priority patent/CH498097A/en
Priority to CH873466A priority patent/CH497393A/en
Publication of CH491873A publication Critical patent/CH491873A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/155Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/16Compounds containing any of the groups, e.g. aminoguanidine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Description

  

  



  Verfahren zur Herstellung von   Phenylalkylaminoguanidinen   
Gegenstand der Erfindung ist ein Verfahren zur Herstellung von   Phenylalkylaminoguanidinen    der Formel: I
EMI1.1     
 sowie von Säure-Additionssalzen davon. In Formel I bedeutet A eine gerade oder verzweigte Alkylengruppe mit   I    bis 4 C-Atomen.   Rr,      R,    und   Rs sind    gleich oder verschieden und stellen Wasserstoff, Halogen, Hydroxyl oder   I    bis 3 C-Atome enthaltendes Alkyl oder Alkoxy dar. Diese Verbindungen wirken hypotensiv und   über-    treffen in dieser Hinsicht bekannte Verbindungen dieser Wirkungsrichtung. Sie dienen somit der Bereicherung des Arzneimittelschatzes.



   Die hypotensive Wirkung von Phenylalkylaminoguanidinen der Formel I und ihrer   Säure-Additions-    salze beruht auf einer Entspeicherung des Neurotransmitters Noradrenalin an den sympathischen Nervenendigungen, wodurch es zu einer Sympathicolyse kommt.



  Pharmakologisch ist dies feststellbar an der Abnahme des Noradrenalingehaltes im Herzen der Maus und am Ausbleiben der   Nickhautkontraktion    bei   prä-und    postganglionärer Reizung des Halssympathicus der Katze.



   Phenylalkylaminoguanidine gemäss Formel I bzw. deren Säure-Additionssalze werden erhalten, wenn man Phenylalkylhydrazine der Formel :
EMI1.2     
 worin A,   Rl,      R.    und   R3    die obengenannte Bedeutung haben bzw. deren Säure-Additionssalze mit Cyanamid umsetzt.



   Soweit nach dem beschriebenen Verfahren freie Basen erhalten wurden, können diese gegebenenfalls nachträglich in ihre Säure-Additionssalze übergeführt werden.



   Als Säure-Additionssalze von Phenylalkylaminoguanidinen der Formel I kommen diejenigen der gebräuchlichen anorganischen und organischen Säuren, wie Salzsäure, Bromwasserstoffsäure, Schwefelsäure, Salpetersäure, Phosphorsäure, Essigsäure, Kohlensäure, Oxalsäure, Weinsäure, Toluolsulfonsäure und dergleichen in Betracht.



   Beispiel 1
Eine Lösung von 20,7 g (0,1   Mol) ss-(p-Chlor-    phenyl) äthylhydrazin-Hydrochlorid und 17,9 g (0,425 Mol) Cyanamid in 100 ml Wasser wird während 8 Stunden auf dem Dampfbad erwärmt. Das Reaktionsprodukt wird durch Zusatz einer Lösung von 9,3 g (0,11 Mol) Natriumbicarbonat in 200 ml Wasser ausgefällt. Das entstandene Bicarbonat wird in 100 ml   n-Propanol    suspendiert und unter Rühren des Reaktionsgemisches mit einer Lösung von   1,    65 ml (0,03 Mol) Schwefelsäure in 25 ml n-Propanol behandelt. Wenn die Kohlen  dioxyd-Entwicklung    beendet ist, wird die Lösung mit Kohle behandelt und filtriert. Nach dem Abkühlen fallen 2,5 g    #- äthylaminoguanidin-   
Semidihydrogensulfat in Form von weissen Plättchen an.

   Durch Konzentration der Mutterlauge werden weitere 7,1 g dieses Produktes erhalten ; die Gesamtausbeute beträgt somit 9,6 g (37   %    der Theorie). Das aus wässrigem Athanol umkristallisierte Produkt zeigt den Schmelzpunkt   192-195  C.   



   Durch Aufnehmen dieses Produktes aus alkalischwässriger Lösung in Chloroform, Eindampfen, Aufnehmen des Rückstandes in wenig Wasser und Zufügen von etwas konzentrierter Salpetersäure erhält man das entsprechende Hydrogennitrat vom Schmelzpunkt 146 bis 147  C (unter Zersetzung ; aus Athanol).



   Bei analogem Vorgehen wie im oben beschriebenen Beispiel erhält man weiterhin, z. B. die in der nachfol  genden    Tabelle II angeführten Verbindungen. In der Kolonne rechts sind in Klammer die Lösungsmittel bzw.



  L¯sungsmittelgemische angegeben, aus welchen Kristallisation erfolgte; dabei bedeuten: Ae êther, Ael êthanol, D Diisopropyläther, I Isopropanol, M Methanol, P   n-Propanol    und W Wasser.



      Tabelle 11    Beispiel A Ri   R=      Form Smp.   



   2 -(CH2)2- H H Hydrogennitrat 145 C (Ael/D)
Semidihydrogenoxalat 213-214 C Zers. (Ael/W)    Hydrochlorid 114-121   C    (P/D)    Semidihydrogencarbonat 109-11 l-C    Zers. (nach Waschen mit   Ael, D)   
Hydrobromid 119-120 C (P/D)
3 -(CH2)2- o-OCH3 H Hydrogennitrat129-132  C (W)    4-    (CH ; r H H   Hydrogennitrat81-84 C(AeI/D)       5-    (CHl) r o-CH3 H   Hydrogennitrat 126-129C C (I)       6-    (CH) m-CH3 H Semidihydrogensulfat 171-174 C Zers. (Ael/D)
Hydrogennitrat 96-98 C (P/W)    7-    (CH2) p-CH3 H   Semidihydrogensulfat 178-184  C (Ael)       Hydrogennitrat 118-119  C    (W)
8 -(CH2)2- o-CH3 H Semidihydrogensulfat 171-176  Zers.

   (Ael/I)    Hydrogennitrat 150-151  C (W/I)   
9 -(CH2)2- p-F H Semidihydrogensulfat 152-155 C (Ael/D)    Hydrogennitrat 123-124C C (W)   
10 -(CH2)2- o-F H Semidihydrogensulfat 170-173 C (Ael/W)
Hydrogennitrat 133-134 C (W)
11 -(CH2)2- p-OCH3 H   Semidihydrogensulfat 207-215  C Zers.

   (Ael W)   
Hydrogennitrat   116-1189 C (Acl)       12-    (CH2) 2-p-Br H   Hydrogennitrat 160-162     C (W)
13 -(CH2)2- m-Cl H   Hydrogennitrat117-120  C (W)   
14 -(CH2)2- o-Cl H Hydrogennitrat 158-160 C (W)
15 -(CH2)2- o-Br H Hydrogennitrat]   58-1622 C    (W)
16 -(CH2)2- 3-Cl 4-Cl Semidihydrogensulfat 230  C (M/D)
17 -(CH2)2- 2-Cl 4-Cl Hydrogennitrat 161-163  C (P)
18 -(CH2)3- o-F H   Hydrogennitrat 783 C (I/D)   
19 -(CH2)3- p-F H Hydrogennitrat 89-92 C (P/D)
20 -(CH2)3- o-Cl H Hydrogennitrat 127 C (Ael/D)
21 -(CH2)3- p-Cl H Hydrogennitrat 126-129  C (W)    22- (CHs) 3- p-CH :

   !    H   Hydrogennitrat 105-107C    C   (I/D)   
23 -(CH2)3- 2-Cl 4-Cl Hydrogennitrat 124-126 C (W)
24 -(CH2)3- 3-Cl 4-Cl Hydrogennitrat 140-142  C   (Wi'I)  



  



  Process for the preparation of phenylalkylaminoguanidines
The invention relates to a process for the preparation of phenylalkylaminoguanidines of the formula: I
EMI1.1
 as well as acid addition salts thereof. In formula I, A denotes a straight or branched alkylene group having 1 to 4 carbon atoms. Rr, R, and Rs are identical or different and represent hydrogen, halogen, hydroxyl or alkyl or alkoxy containing 1 to 3 carbon atoms. These compounds have a hypotensive effect and in this respect exceed compounds known in this regard. They thus serve to enrich the treasure trove of medicines.



   The hypotensive effect of phenylalkylaminoguanidines of the formula I and their acid addition salts is based on the depletion of the neurotransmitter noradrenaline at the sympathetic nerve endings, which leads to sympathicolysis.



  This can be determined pharmacologically from the decrease in the noradrenaline content in the heart of the mouse and the absence of nictitating membrane contraction in the case of pre- and postganglionic irritation of the cat's cervical sympathetic nerve.



   Phenylalkylaminoguanidines according to formula I or their acid addition salts are obtained when phenylalkylhydrazines of the formula:
EMI1.2
 wherein A, Rl, R. and R3 have the abovementioned meaning or their acid addition salts react with cyanamide.



   If free bases were obtained by the process described, these can optionally be converted into their acid addition salts subsequently.



   Suitable acid addition salts of phenylalkylaminoguanidines of the formula I are those of the customary inorganic and organic acids, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, acetic acid, carbonic acid, oxalic acid, tartaric acid, toluenesulfonic acid and the like.



   example 1
A solution of 20.7 g (0.1 mol) of ss- (p-chlorophenyl) ethyl hydrazine hydrochloride and 17.9 g (0.425 mol) of cyanamide in 100 ml of water is heated on the steam bath for 8 hours. The reaction product is precipitated by adding a solution of 9.3 g (0.11 mol) of sodium bicarbonate in 200 ml of water. The bicarbonate formed is suspended in 100 ml of n-propanol and treated with a solution of 1.65 ml (0.03 mol) of sulfuric acid in 25 ml of n-propanol while stirring the reaction mixture. When the development of carbon dioxide has ended, the solution is treated with charcoal and filtered. After cooling, 2.5 g of ethylaminoguanidine
Semi-dihydrogen sulfate in the form of white platelets.

   Concentration of the mother liquor gives a further 7.1 g of this product; the total yield is thus 9.6 g (37% of theory). The product recrystallized from aqueous ethanol has a melting point of 192-195 C.



   By taking up this product from an aqueous alkaline solution in chloroform, evaporating, taking up the residue in a little water and adding a little concentrated nitric acid, the corresponding hydrogen nitrate is obtained with a melting point of 146 to 147 ° C. (with decomposition; from ethanol).



   With an analogous procedure as in the example described above, one still obtains, for. B. the compounds listed in the following Table II. In the column on the right, the solvents resp.



  Solvent mixtures indicated from which crystallization took place; where: Ae êther, Ael êthanol, D diisopropyl ether, I isopropanol, M methanol, P n-propanol and W water.



      Table 11 Example A Ri R = Form Smp.



   2 - (CH2) 2- H H hydrogen nitrate 145 C (Ael / D)
Semidihydrogen oxalate 213-214 C dec. (Ael / W) hydrochloride 114-121 C (P / D) semidihydrogen carbonate 109-11 l-C dec. (after washing with Ael, D)
Hydrobromide 119-120 C (P / D)
3 - (CH2) 2- o-OCH3 H hydrogen nitrate 129-132 C (W) 4- (CH; r HH hydrogen nitrate 81-84 C (AeI / D) 5- (CHl) r o-CH3 H hydrogen nitrate 126-129C C ( I) 6- (CH) m-CH3 H semi-dihydrogen sulfate 171-174 C decomp. (Ael / D)
Hydrogen nitrate 96-98 C (P / W) 7- (CH2) p-CH3 H Semi-dihydrogen sulfate 178-184 C (Ael) Hydrogen nitrate 118-119 C (W)
8 - (CH2) 2- o-CH3 H semi-dihydrogen sulfate 171-176 dec.

   (Ael / I) hydrogen nitrate 150-151 C (W / I)
9 - (CH2) 2- p-F H semi-dihydrogen sulfate 152-155 C (Ael / D) hydrogen nitrate 123-124C C (W)
10 - (CH2) 2- o-F H semi-dihydrogen sulfate 170-173 C (Ael / W)
Hydrogen Nitrate 133-134 C (W)
11 - (CH2) 2- p-OCH3 H semi-dihydrogen sulfate 207-215 C dec.

   (Ael W)
Hydrogen nitrate 116-1189 C (Acl) 12- (CH2) 2-p-Br H Hydrogen nitrate 160-162 C (W)
13 - (CH2) 2- m-Cl H hydrogen nitrate 117-120 C (W)
14 - (CH2) 2- o-Cl H hydrogen nitrate 158-160 C (W)
15 - (CH2) 2- o-Br H hydrogen nitrate] 58-1622 C (W)
16 - (CH2) 2- 3-Cl 4-Cl semi-dihydrogen sulfate 230 C (M / D)
17 - (CH2) 2- 2-Cl 4-Cl hydrogen nitrate 161-163 C (P)
18 - (CH2) 3- o-F H hydrogen nitrate 783 C (I / D)
19 - (CH2) 3- p-F H hydrogen nitrate 89-92 C (P / D)
20 - (CH2) 3- o-Cl H hydrogen nitrate 127 C (Ael / D)
21 - (CH2) 3- p-Cl H hydrogen nitrate 126-129 C (W) 22- (CHs) 3- p-CH:

   ! H hydrogen nitrate 105-107C C (I / D)
23 - (CH2) 3- 2-Cl 4-Cl hydrogen nitrate 124-126 C (W)
24 - (CH2) 3- 3-Cl 4-Cl hydrogen nitrate 140-142 C (Wi'I)

 

Claims (1)

PATENTANSPRUCH Verfahren zur Herstellung von Phenylalkylaminoguanidinen der Formel : EMI2.1 worin A eine gerade oder verzweigte Alkylengruppe mit 1 bis 4 C-Atomen bedeutet, R1, R2 und Rs gleich oder verschieden sind und Wasserstoff, Halogen, Hydroxyl oder 1 bis 3 C-Atome enthaltendes Alkyl oder Alkoxy darstellen, sowie von Säure-Additionssalzen davon, dadurch gekennzeichnet, dass man Phenylalkyl- hydrazine der Formel : EMI2.2 worin A, R1, R2 und R : ; die obengenannte Bedeutung haben bzw. deren Säure-Additionssalze mit Cyanamid umsetzt, gegebenenfalls unter nachträglicher Überfüh- rung von erhaltenen freien Basen in ihre Säure-Addi tionssalze. PATENT CLAIM Process for the preparation of phenylalkylaminoguanidines of the formula: EMI2.1 where A is a straight or branched alkylene group with 1 to 4 carbon atoms, R1, R2 and Rs are identical or different and represent hydrogen, halogen, hydroxyl or alkyl or alkoxy containing 1 to 3 carbon atoms, and acid addition salts thereof , characterized in that one phenylalkyl hydrazines of the formula: EMI2.2 wherein A, R1, R2 and R:; have the abovementioned meaning or their acid addition salts are reacted with cyanamide, optionally with subsequent conversion of the free bases obtained into their acid addition salts.
CH801766A 1964-05-05 1964-05-05 Process for the preparation of phenylalkylaminoguanidines CH491873A (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CH801766A CH491873A (en) 1964-05-05 1964-05-05 Process for the preparation of phenylalkylaminoguanidines
CH898866A CH498097A (en) 1964-05-05 1965-11-15 2 6-dihalophenylalkylamino guanidines useful as
CH873466A CH497393A (en) 1964-05-05 1966-06-16 Phenylakylaminoguanidines used as hypoten - sives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH585464A CH448057A (en) 1964-05-05 1964-05-05 Process for the preparation of phenylalkylaminoguanidines
CH801766A CH491873A (en) 1964-05-05 1964-05-05 Process for the preparation of phenylalkylaminoguanidines

Publications (1)

Publication Number Publication Date
CH491873A true CH491873A (en) 1970-06-15

Family

ID=4300408

Family Applications (3)

Application Number Title Priority Date Filing Date
CH801666A CH511216A (en) 1964-05-05 1964-05-05 Phenylalkylamino guanidines
CH585464A CH448057A (en) 1964-05-05 1964-05-05 Process for the preparation of phenylalkylaminoguanidines
CH801766A CH491873A (en) 1964-05-05 1964-05-05 Process for the preparation of phenylalkylaminoguanidines

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CH801666A CH511216A (en) 1964-05-05 1964-05-05 Phenylalkylamino guanidines
CH585464A CH448057A (en) 1964-05-05 1964-05-05 Process for the preparation of phenylalkylaminoguanidines

Country Status (15)

Country Link
JP (1) JPS4842627B1 (en)
AT (3) AT255433B (en)
BE (1) BE663481A (en)
BR (1) BR6569419D0 (en)
CH (3) CH511216A (en)
CS (1) CS151461B2 (en)
DE (1) DE1518222A1 (en)
DK (2) DK107288C (en)
ES (1) ES312384A1 (en)
FI (1) FI42316B (en)
FR (1) FR4399M (en)
GB (1) GB1096348A (en)
IL (1) IL23443A (en)
NL (1) NL6505684A (en)
SE (2) SE317057B (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR200F (en) * 1965-11-15
US3541218A (en) * 1969-06-18 1970-11-17 Lilly Co Eli Omicron-fluorobenzylaminoguanidine for diabetes
JPS5051717U (en) * 1973-09-06 1975-05-19
JPS5391735U (en) * 1976-12-27 1978-07-27
JPS54121027U (en) * 1978-02-13 1979-08-24
EP0021120B1 (en) * 1979-06-01 1983-04-06 The Wellcome Foundation Limited 3,5-diamino-1,2,4-triazine derivatives, process for preparing such compounds and pharmaceutical compositions containing them
GR68380B (en) * 1979-06-01 1981-12-28 Wellcome Found
FR2549049B1 (en) * 1983-07-13 1986-06-20 Chauvin Blache Lab NEW AMIDINES, THEIR PREPARATION PROCESS AND THEIR THERAPEUTIC APPLICATION
HU190639B (en) * 1983-12-12 1986-09-29 Gyogyszerkutato Intezet Kv,Hu Process for production of new aminoguanidin derivatives
EP0325936A3 (en) * 1988-01-16 1990-01-17 Ono Pharmaceutical Co., Ltd. Aminoguanidine derivatives and inhibitory agents on maillard reaction containing them as active ingredients
US5891909A (en) * 1996-03-29 1999-04-06 3-Dimensional Pharmaceuticals, Inc. Amidinohydrazones as protease inhibitors
TW499412B (en) * 1996-11-26 2002-08-21 Dimensional Pharm Inc Aminoguanidines and alkoxyguanidines as protease inhibitors
KR20030022353A (en) 2000-08-04 2003-03-15 3-디멘져널 파마슈티칼즈 인코오포레이티드 Cyclic oxyguanidine protease inhibitors

Also Published As

Publication number Publication date
BE663481A (en)
CH511216A (en) 1971-08-15
GB1096348A (en) 1967-12-29
CS151461B2 (en) 1973-10-19
AT255433B (en) 1967-07-10
JPS4842627B1 (en) 1973-12-13
FI42316B (en) 1970-03-31
DK107288C (en) 1967-05-16
ES312384A1 (en) 1966-03-01
DE1518222A1 (en) 1969-06-12
CH448057A (en) 1967-12-15
NL6505684A (en) 1965-11-08
FR4399M (en) 1966-09-05
SE371640B (en) 1974-11-25
IL23443A (en) 1968-09-26
SE317057B (en) 1969-11-10
AT255432B (en) 1967-07-10
AT255434B (en) 1967-07-10
DK111887B (en) 1968-10-21
BR6569419D0 (en) 1973-08-02

Similar Documents

Publication Publication Date Title
CH491873A (en) Process for the preparation of phenylalkylaminoguanidines
DE602005003678T2 (en) MIXED OLANZAPINE SOLVATE, METHOD FOR THE PRODUCTION THEREOF, AND METHOD FOR THE PRODUCTION OF OLANZAPINE FORM I THEREOF
DE1518764C3 (en) S-phenyl-2-oxo-23-dihydro-1H-1 ^ -benzodiazepine-S-carboxylic acid salts and alkyl esters substituted in the 7-position
DE1172671B (en) Process for the preparation of 17ª-hydroxy-androstane-(3, 2-c)-pyrazole or a 17ª-hydroxy-17ª-lower-alkyl-androstane-(3, 2-c)-pyrazole
DE2145321A1 (en) Process for the production of potassium peroxide sulfate
CH497393A (en) Phenylakylaminoguanidines used as hypoten - sives
DE1620538C (en) Vitamin B deep 1 derivative
AT217048B (en) Process for the preparation of new theophylline derivatives substituted in the 7-position
DE1695363C3 (en) 1H-3.4 dihydro-2,3 benzoxazine and its substituted derivatives and processes for the preparation of these compounds
DE959052C (en) Light stabilizers
DE2323423A1 (en) PROCESS FOR THE PRODUCTION OF EBURNAMONINES
DE2218248C3 (en) Picolinic acid dithiocarbamates
DE1518262C (en) Pharmacologically acceptable acid addition salts of 2 (1 guanidinoethyl) 1,4 benzdioxanes and process for their manufacture
DE1470157C (en) 2 Dimethyl sulfate! ^ 9 square brackets on 3 (4 methylpiperazino) propylidene square brackets on thioxanthene, its cis / trans isomers, their salts and process for the preparation of these compounds
AT228203B (en) Process for the preparation of new 11b-benzo (a) -quinolizine derivatives
DE1470127A1 (en) Process for the preparation of dibenzocycloheptane derivatives and preparations containing them
CH631714A5 (en) Process for preparing novel quaternary derivatives of sandwicin
DE1100646B (en) Process for the production of crystallized sodium glutamate
CH530964A (en) Phenylalkylaminoguanidine cpds prodn - with hypotensive action
DE2916990A1 (en) PROCESS FOR THE PREPARATION OF 1- (P-CHLOROPHENOXYACETYL) -4-PIPERONYLPIPERAZINE HYDROCHLORIDE
DE1620543A1 (en) Process for the preparation of new dibenzo [b, f] [1,5] diazocines
DE1258416B (en) Process for the preparation of L-alpha-methyl-beta- (3, 4-dihydroxyphenyl) -alanine
DE1062252B (en) Process for the preparation of 1-oxy-4, 5, 6, 7, 10, 10-hexachlor-4, 7-endomethylene-4, 7, 8, 9-tetrahydrophthalane
CH533603A (en) Phenylalkylaminoguanidines - with hypotensive activity
DE1079066B (en) Process for the preparation of substituted coumarones

Legal Events

Date Code Title Description
PL Patent ceased